These results led us to evaluate Nano-11 and NanoST as adjuvant platforms for STING-targeted cancer immunotherapy in mouse models of melanoma and lymphoma, in which OVA functions as a tumor-specific antigen. The gene discussed is STING1; the disease is lymphoma.